Related Experiment Videos
Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter
1Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.
Abstract:
p16(INK4a) is frequently altered in human cancer, often through epigenetically mediated transcriptional silencing. However, little is known about the transcriptional regulation of this gene. To learn more about such control, we initiated studies of proteins that bind to the promoter in cancer cells that do, and do not, express the gene. We identify RNA helicase A (RHA) as a protein that binds much better to the p16(INK4a) promoter in the expressing cells. RHA has not previously been characterized to manifest sequence-specific DNA interaction but does so to the sequence 5' CGG ACC GCG TGC GC 3' in the p16(INK4a) promoter. The Drosophila homologue to RHA, maleless (Mle), functions in the fly for 2-fold activation of male X-chromosome genes. In our experimental setting, RHA induces a similar modest up-regulation of the p16(INK4a) promoter that is dependent upon its sequence-specific interaction. Mle colocalizes with hyperacetylated H4Ac16 on the X-chromosome and some autosomal loci. The decreased binding of RHA to p16(INK4a) in our cells, where the gene is transcriptionally inactive, is associated with decreased amounts of RHA that immunoprecipitate with acetylated lysine antibodies. Finally, we show RHA to be a cellular substrate for caspase-3, which decreases its sequence-specific binding to p16(INK4a) by cleavage of the N terminus. Thus, we have identified a new protein interaction with the p16(INK4a) promoter that involves an important protein for transcriptional modulation. This interaction is decreased in cancer cells, where this gene is aberrantly transcriptionally silent.
Insights
RNA helicase A (RHA) binds the p16(INK4a) promoter, regulating gene expression. This binding is reduced in cancer cells, correlating with gene silencing and RHA
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- The p16(INK4a) gene is frequently altered in human cancers, often via epigenetic silencing.
- Transcriptional regulation of p16(INK4a) is not well understood.
- Investigating proteins interacting with the p16(INK4a) promoter is crucial for understanding its expression control.
Purpose of the Study:
- To identify proteins that bind to the p16(INK4a) promoter in cancer cells with differing expression levels.
- To characterize the role of RNA helicase A (RHA) in p16(INK4a) transcriptional regulation.
- To explore mechanisms affecting RHA binding and p16(INK4a) expression in cancer.
Main Methods:
- Protein-DNA binding assays to identify factors interacting with the p16(INK4a) promoter.
- Sequence-specific DNA binding analysis of RNA helicase A (RHA).
- Immunoprecipitation and Western blotting to assess RHA interaction with acetylated histones and caspase-3 cleavage.
Main Results:
- RNA helicase A (RHA) binds specifically to the p16(INK4a) promoter sequence 5' CGG ACC GCG TGC GC 3'.
- RHA binding is significantly reduced in cancer cells where p16(INK4a) is transcriptionally silent.
- Caspase-3 cleavage of RHA's N-terminus decreases its sequence-specific DNA binding activity.
Conclusions:
- RNA helicase A (RHA) is identified as a novel protein that modulates p16(INK4a) transcription.
- Reduced RHA binding to the p16(INK4a) promoter is associated with transcriptional silencing in cancer.
- RHA's interaction with p16(INK4a) is regulated by caspase-3, offering a potential mechanism for aberrant gene silencing in cancer.